In 2016, the FDA approved the first drug, Nusinersen, as an anti-sense oligonucleotide (ASO) treatment of SMA, which increases SMN expression through alternative splicing of SMN2 pre-mRNA. Here, SMN1 is linked to proximal spinal muscular atrophy.